One of the lead doctors associated with Pfizer’s efforts to develop a COVID-19 vaccine said yesterday on WBLQ’s Morning Show that Pfizer is expanding its clinical trial to include participants as young as 12, with no upper age requirement, and that the vaccine could receive emergency authorization by the end of the year.
Dr. Onyema E. Ogbuagu, an infectious disease specialist, virologist and principal investigator of the Pfizer trail at Yale New Haven Hospital, said Pfizer is expanding the trail pool from 30,000 and ages 18 to 85 to 44,000 individuals from12 to no upper age limit.
Dr. Ogbuagu was a guest on the Westerly’s station’s Morning Show, hosted by Frank Prosnitz. Dr. Ogbuagu is affiliated with Yale New Haven Hospital, which is the parent of Westerly Hospital and nearby Lawrence & Memorial in New London, Ct.
The Pfizer study is among more than 130 worldwide, five of which are in stage 3 trials, Dr. Ogbuagu said.
Stage 3 is the final stage before approval and distribution. Most studies are in phase 1 or 2, with a handful at stage 3 and two that are actually in limited distribution, although their efficacy in question. Those two are from China and Russia, rushed into production before reaching stage 3 trials, with experts concerned that the rushed process poses potential serious risks.
Dr. Ogbuagu said that Pfizer and Moderna are the two companies closest to approval. Moderna has received more than $2 billion in government support. Canada has already agreed to acquire 20 million doses from Moderna, once the vaccine is approved.
A vaccine goes through several stages: Preclinical tests in which scientists give the vaccine to animals; phase 1 safety trials in which scientists administer the vaccine to a small number people; phase 2, in which the vaccine is given to hundreds of people, separately participants into groups; and phase 3 efficacy trials in which thousands of people receive the vaccine.
Typically, Dr. Ogbuagu said, trials are designed to last two years. The studies are data-driven, he said, with stops at various points for data review. The next “interim analysis,” Dr. Ogbuagu said, is scheduled for sometime in November.
He said, “things are going well,” but cautioned about the importance of following the science and adhering to FDA standards.
“The FDA has very reasonable standards,” Dr. Ogbuagu said. “The FDA should be ideally independent.”
The Latest From WUN
- Obituary: Julian C. Clinton
- “Six Picks” Pumpkin Ale – It’s the time of the season
- Holidays at the Newport Mansions returns to The Breakers, Marble House, and The Elms starting November 20
- Oakland Forest in Portsmouth will be inducted into the national Old-Growth Forest Network
- Stop & Shop to hold a one-day career fair at all 27 Rhode Island locations